Please contact us for any questions.

Related Posts




Project Information

Call name: Eurostars 3 – Call 1
Application name: A hybrid clinical trial and application tool for transcatheter aortic valve replacement
Application acronym: HYBRID-TAVR
Start of the project: 1 June 2022
End of the project: 31 May 2024
Main project applicant: Hi-D Imaging AG (Switzerland)
Project partner: ELEM Biotech SL (Spain)


Hi-D Imaging and ELEM Biotech develop and commercialize decision-making support software for patient-specific diagnosis and treatment of cardiac diseases using data-driven and physics-based models respectively. Despite improved outcome of Transcatheter Aortic Valve Implantation (TAVI) in high, intermediate and low-risk patients with severe aortic stenosis and aortic regurgitation, some individuals exhibit less clinical improvement post-TAVI. Making use of the synergy between companies, it is aimed to develop a novel medical device performance analysis tool to optimize the total product life cycle of TAVIs.

Interested for a collaboration?

Contact us over [email protected]

We are looking forward hearing from you!